Showing results (101-110 of 6,998) with videos related to

Sort By:
Pageof 700
Lung Cancer (Amsterdam, Netherlands)|November 7, 2025
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS studyHyun Ae Jung, Tae Min Kim, Hye Ryun Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2025
Plasma proteomics profiling identifies predictive biomarkers for immunotherapy response in small-cell lung cancerGuang-Ling Jie, Jia-Xin Zhong, Jing-Ze Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2025
The immune desert tumor microenvironment in Thoracic SMARCA4-deficient undifferentiated tumors: spatial distribution characteristics and prognostic significanceXiaotao Wang, Wenwen Shi, Yang Xiao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2025
A novel agent, p-toluenesulfonamide, in the management of malignant pleural effusionsYung-Hung Luo, Chuan-Ching Yang, Shun-Chi Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2025
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)Paolo Borghetti, Rolando D'Angelillo, Giorgio Facheris, et al.
Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.
Lung Cancer (Amsterdam, Netherlands)|October 10, 2025
Comparative analysis of the tumor immune microenvironment between thymoma and thymic carcinomaShoko Sonobe Shimamura, Takehito Shukuya, Makiko Yamashita, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effectsMeng Liu, Jeffrey P Townsend
Lung Cancer (Amsterdam, Netherlands)|September 25, 2025
Patterns of treatment prior to death among those with lung cancer: A national study in a universal healthcare contextJ Gurney, D Ongley, L Cameron, et al.
Pageof 700